Evidence map›Paper›PMID 40295027›Full record

ArticleIn vivo (Athens, Greece)

Modified Advanced Lung Cancer Inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.

Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Ryuki Esashi, Sosuke Yamamoto, Kiyoko Shimada, Keisuke Kazama, Ayako Tamagawa, Mie Tanabe, Keisuke Komori and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Toru Aoyama *Department of Surgery, Yokohama City University, Yokohama, Japan t-aoyama@lilac.plala.or.jp.
Itaru Hashimoto *Department of Surgery, Yokohama City University, Yokohama, Japan.
Yukio MaezawaDepartment of Surgery, Yokohama City University, Yokohama, Japan ykzawa0@gmail.com.
Ryuki EsashiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Sosuke YamamotoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kiyoko ShimadaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KazamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Ayako TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Mie TanabeDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KomoriDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Natsumi KamiyaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Naoko OkudaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Koji NumataDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Mamoru UchiyamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimBody composition changes and nutritional status affect the oncological outcomes in various malignancies. Modified advanced lung cancer inflammation index (mALI) evaluates both body composition changes and nutritional status. Herein, we aimed to examine the potential of mALI as a biomarker for gastric cancer (GC). PATIENTS AND

methodsThe medical records of 327 consecutive patients with gastric cancer who underwent curative resection at Yokohama City University from 2015 to 2022 were retrospectively reviewed. mALI was defined follows: Appendicular skeletal muscle index×Serum albumin/Neutrophil-to-lymphocyte ratio. The clinical impact of the mALI on the short- and long-term oncological outcomes was evaluated using Kaplan-Meier curves and Cox's proportional hazards models.

resultsThe 327 patients were classified into the mALI-low (n=121) and mALI-high (n=206) groups, respectively. The 1-, 3-, and 5-year overall survival (OS) rates were 94.0%, 71.4%, and 59.2%, respectively, in the mALI-low group, and 95.5%, 85.0%, and 79.9%, in the mALI-high group. In the multivariable analysis for OS, the mALI was identified as an independent prognostic factor [hazard ratio (HR)=1.794; 95% confidence interval (CI)=1.155-2.786,

conclusionThe mALI was an independent prognostic factor for OS and RFS in patients with GC. Our results suggest that the mALI is a promising biomarker for GC and a useful tool for the treatment and management of GC.

Indexed as

InflammationLung NeoplasmsStomach NeoplasmsAdultAgedBiomarkers, TumorFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesBiomarkers, Tumorbody composition changesGastric cancermALIsurvival

Identifiers

PMID40295027
PMCPMC12041965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.